NCT01766466

Cangrelor Ticagrelor Transition Study

A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: The Medicines Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	cangrelor	Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
DRUG	Ticagrelor	Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.

Timeline

• Start date: 2013-01-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2013-01-11
• Last updated: 2014-05-19
• Results posted: 2014-05-19

Locations

1 site across 1 country: United States